Gain deeper insights into the mechanisms of immune cell killing of tumor cells: accelerate your time to answer with integrated software analysis
Oct
6
2021
On demand

Gain deeper insights into the mechanisms of immune cell killing of tumor cells: accelerate your time to answer with integrated software analysis

Wednesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST
Sponsor
Gain deeper insights into the mechanisms of immune cell killing of tumor cells: accelerate your time to answer with integrated software analysis

Understanding the processes of the immune system and interactions at a cellular level is essential to identifying and validating new targets and determining cellular therapy approaches. Advanced cell analysis tools are successfully used for unlocking the secret to immune cell interactions and potentially enabling future breakthroughs in immune-based therapies. Integrated software analysis is key component of advanced cell analysis platforms, allowing for interactive assay development and the evaluation of large data sets through multiparameter data visualization. From linking well data together to combining multiple assay outcomes to identify “hits”, integrated software analysis can quickly provide the data insights you need to accelerate the drug discovery process.

Flow cytometry has been used extensively to study immune cells, yielding information regarding cellular subtypes, activation status and viability using expression profiles and cell health markers. In recent years, live-cell analysis has become an established method by which temporal and spatial information can be gained from the interactions and resultant killing of tumor cells

  • How to generate more biologically-relevant data through simultaneous measurements of phenotypes and functions in the same well
  • How to use real-time data acquisition and analysis to accelerate the path to actionable results, even from complex data sets
  • Efficiencies from utilizing a single software solution to guide metrics, statistics, visualizations, and reports
  • How to use dynamic visualization of results to compare, identify, and rank wells in all plates across your experiment
Colby Souders PhD
Colby Souders PhD
Chief Scientific Officer, Abveris
Colby Souders holds a PhD in Cell and Molecular Biology from Texas A&M and prior to Abveris was part of MassBiologics of the University of Massachusetts Medical School and Kanyos Bio (now Anokion). At MassBiologics, he worked to advance monoclonal antibodies for the prevention, treatment or diagnosis of various infectious and endogenous diseases, as well as develop related platform technologies to advance and expand the MassBiologics pipeline. Later, he joined the Kanyos Bio Protein Engineering team to develop therapeutics based on a novel antigen-specific immune tolerance platform. After successful completion of multiple antibody discovery, affinity maturation and protein engineering campaigns using various in vivo and in vitro techniques, Colby joined Abveris in August of 2018. As Chief Scientific Officer, he helps guide the team to usher in a new generation of antibody discovery tools and work to build a premium discovery engine with industry-leading timelines.
Tim Dale PhD
Tim Dale PhD
Head of BioAnalytics Applications, Sartorius
Tim joined Sartorius through the acquisition of Essen BioScience in 2017 and is currently Head of BioAnalytics Applications. Co-founder of the Essen BioScience European laboratories in 2009, Tim managed R&D operations. Tim’s experience in small molecule drug discovery has contributed to several candidate molecules progressing into clinical studies. He has co-authored over 20 publications relating to pharmacology, ion channels and cell-based assays.
Nicola Bevan
Nicola Bevan
Manager of Cell Imaging Applications, Sartorius
Nicola Bevan manages a Cell Imaging Applications group within the European-based BioAnalytics research team where she is involved in the research and development of novel applications for the Incucyte® live-cell analysis system and iQue® high-throughput cytometer.Nicola is a highly experienced cellular pharmacologist, having worked for more than 25 years in the pharma and biotech industry in various roles including in industrial screening and early drug discovery programs.
Jeffrey Skolnik MD
Jeffrey Skolnik MD
Senior Vice President, Clinical Development, Inovio
Dr. Skolnik leads the HPV and immuno-oncology teams at Inovio, a DNA medicines biotechnology company. Dr. Skolnik has overseen teams at both small biotechnology and large pharmaceutical companies, where he has held several leadership positions in Clinical Development and Medical Affairs. Jeffrey is a pediatric oncologist by training, and continues to serve on staff as an Attending Physician at the Children’s Hospital of Philadelphia.